This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Roger Sachs, MD
Pfizer Laboratories Division New York

JAMA. 1985;254(9):1175.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

There are several scientific flaws in the recent article by Boden et al¹ discussing the proposed pathophysiologic mechanisms of paradoxical myocardial ischemia in the treatment of patients with refractory angina who are taking nifedipine coadministered with β-blockers or long-acting nitrates. The first problem is the basic study design. The authors studied a subset of patients who had experienced recurrent episodes of angina pectoris following nifedipine administration and, in an uncontrolled, nonrandomized, open fashion, evaluated each patient's response to study medications. Although the study attempted to investigate the pathophysiologic mechanisms of paradoxical angina, this uncontrolled design introduces both patient and investigator bias. Certainly, the patients' psychological and physiological response to a regimen that they expect will cause them pain must confound the validity of any results obtained from the trial.

A second major problem is the apparent lack of nifedipine titration. Despite the fact that the patients . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?